High hopes as Inventiva takes NASH contender into phase 3Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, Share XHigh hopes as Inventiva takes NASH contender into phase 3https://pharmaphorum.com/news/high-hopes-as-inventiva-takes-nash-contender-into-phase-3/
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruitTwo years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a Share XNovo Nordisk’s gene silencing alliance with Dicerna bears first fruithttps://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/
Lilly surges on positive phase 3 readout from diabetes contenderEli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be Share XLilly surges on positive phase 3 readout from diabetes contenderhttps://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/
Gilead and Novo plot next steps after trial data from NASH comboGilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked Share XGilead and Novo plot next steps after trial data from NASH combohttps://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/
Towards a new understanding of cardiovascular risk in diabetesA new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is Share XTowards a new understanding of cardiovascular risk in diabeteshttps://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/
Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnNovo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion, as it continues its quest to develop Share XNovo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnhttps://pharmaphorum.com/news/novo-nordisk-to-buy-emisphere-and-diabetes-pill-tech-for-1-8bn/
Price cut leads NICE to back Novo Nordisk’s obesity drug SaxendaNovo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in Share XPrice cut leads NICE to back Novo Nordisk’s obesity drug Saxendahttps://pharmaphorum.com/news/price-cut-leads-nice-to-back-novo-nordisks-obesity-drug-saxenda/
Novo launches type 2 diabetes pill in UK after NICE waives reviewNovo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE Share XNovo launches type 2 diabetes pill in UK after NICE waives reviewhttps://pharmaphorum.com/news/novo-launches-type-2-diabetes-pill-in-uk/
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetesIn our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he Share XNovo Nordisk: Prevention, digital tools and collaboration to define the future of diabeteshttps://pharmaphorum.com/views-analysis-sales-marketing/novo-nordisk-prevention-digital-tools-and-collaboration-to-define-the-future-of-diabetes/
